Check out VVUS here.
With the short interest in Vivus shares over 15,000,000 shares and the attention that the weight loss drugs have been getting in recent months the share price will hit $60.00 with the approval.
Dendreon went to $58.50. Vivus has $185,000,000 in cash on hand and a partnership for Avanafil, its erectile dysfunction drug that acts twice as fast as Viagra, is likely to be announced at any time. Other drugs in the pipeline.
JMP Healthcare Securities Conference Presentation
Qnexa’s PDUFA Date – 10/28/2010 Approval Takes It To $30.00
“New Buy Rating On Vivus”
Vivus’ Avanafil Performs Better than Cialis or Viagra
Potential Partnership At Anytime
I was correct on BP and I'll be more than correct on "BIOD". 200-300% upside at the current price.
PDUFA date for its insulin drug in October.
Big pharma partnership or buyout triples the current share price.
“5 Stocks That Analysts Expect To Double” – “BIOD” – Price Target: $16.00
“Seeking Alpha Overview of Biodel, Inc. – “BIOD”
Seeking Alpha – "Why Biodel's VIAject Could Revolutionize Diabetes Care"
Seeking Alpha – "Biodel, Inc. – "BIOD" – Small Bio-Tech With Big Upside
Seeking Alpha – "Why Biodel Is Breathing Easy – Part 1"
Seeking Alpha – "Why Biodel Is Breathing Easy – Part 2"
Rite-Aid is a perfect candidate for a takeover. Potential suitors are Wal-Mart, Target Stores, CVS, and Walgreens.
As a rather simplistic approach to valuation compare Walgreens to Rite Aid. Walgreen's current market cap values each of their stores at about $7,000,000/store. Rite-Aid's current market cap values each of their stores at about $220,000. It seems that this simple approach provides substantial upside to the current share price which is near the 52 week low.
Rite-Aid recently posted a smaller than expected loss for the recent quarter.
Rite-Aid recently named a new Chief Operating Officer.
If you liked my call on BP and TIVO then today is the day to purchase MNKD. Partnership new could double or triple the share price.
Mannkind’s management stated that it expected to announce a "big pharma" partnership after the resubmission of the NDA which is expected to occur in the next ten days. Company has also stated that it is seeking a partner for its cancer drug.
Charles Schwab Added 1,459,000 Shares On 7/2/2010
Mannkind: Rodman & Renshaw Reiterates Buy on Afrezza Data
Mannkind (MNKD) reinstated at Bank of America/Merrill Lynch with a “Buy Rating” and $18.00 Price Target.